Fludarabine
EGFR Positive Solid Tumor
Fate TherapeuticsSmall moleculePhase 1Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the EGFR Positive Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Fate Therapeutics | Phase 1 | CCC |
Fate-Nk100 Fate Therapeutics | Phase 1 | CC |
Epirubicin Fate Therapeutics | Phase 1 | CC |
Nivolumab Fate Therapeutics | Phase 1 | CC |
TRASTUZUMAB Fate Therapeutics | Phase 1 | CC |
View all 10 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →